Investment Pitches

Pitch Summary:
Robinhood is a retail trading platform whose earnings power is being capitalized at peak-on-peak conditions during a speculative mania in crypto, options, and high-turnover retail trading. The bear case argues that HOOD is fundamentally a highly cyclical, high-decremental-margin business trading at ~50x inflated EPS, with over half of profits tied to “YOLO” activities like crypto and options. While bulls frame the company as a Gen Z financial super-app, the underlying economics resemble a casino with volatile revenues, modest customer asset quality, and declining marginal monetization. Sequential revenues have already flattened despite strong market conditions, suggesting saturation among its most lucrative users. Any normalization in trading volumes, asset prices, or interest rates would hit earnings sharply given 90%+ decremental margins. With limited upside after S&P inclusion and crowded hedge fund long positioning, the setup favors a large downside move if retail speculation cools.

BSD Analysis:
Robinhood is a "gamified" financial super-app that monetizes retail speculation via PFOF (Payment for Order Flow) and net interest spreads. Sector: The brokerage sector is currently benefiting from a "retail frenzy," but structural risks include regulatory crackdowns on "prediction markets" and shrinking interest spreads. Dynamics: The distribution model relies on low-friction onboarding and viral social features (Robinhood Social) to maintain an active, high-churn user base. The dynamic is heavily skewed toward "YOLO" trades (Crypto/Options), creating high sensitivity to market volatility and "meme" cycles. Robinhood’s wallet share is expanding into banking and credit, but these products carry higher operational costs and lower capital efficiency than its legacy trading business. The "generational wealth transfer" story is viewed as a risk; as younger users inherit larger sums, they may migrate toward established institutional advisors (Schwab/Fidelity) for professional management.

Pitch Summary:
Astera Labs is a fabless data-center semiconductor company whose rapid revenue growth has been driven by a narrow set of products aligned to a specific moment in AI infrastructure design. The pitch argues the company successfully monetized early PCIe retimer and smart cable demand but is now extrapolated as a durable platform with an ever-expanding TAM. In reality, each of Astera’s four product families—retimers, active electrical cables, CXL memory controllers, and PCIe switches—faces material structural or competitive pressure over the next 6–24 months. NVIDIA’s system-level integration is reducing the need for retimers and discrete PCIe switches in next-gen GPU architectures. In AECs, Astera appears to be a late, me-too entrant competing against entrenched leaders with slipping roadmap execution. CXL adoption remains niche as GPU designs prioritize bandwidth-dense alternatives over PCIe-based memory pooling. With ~87% of revenue concentrated among the top five customers and AWS economics distorted by warrant incentives, revenue quality is weaker than headline growth implies. At ~40x+ LTM revenue, the stock prices sustained dominance that is increasingly misaligned with product reality.

BSD Analysis:
ALAB operates in the "signal integrity" niche, selling specialized retimers and switches that fix data timing errors (jitter and skew) in high-speed server links. Sector: The AI connectivity sector is currently in a state of hyper-growth, but is rapidly moving toward "platformization" where major GPU and NIC vendors (NVIDIA, Broadcom) are integrating connectivity features into their own silicon. Dynamics: The company's distribution is highly concentrated, with a few major hyperscalers—most notably Amazon (AWS)—representing the bulk of revenue. A critical dynamic is the Amazon warrant agreement, where AWS is incentivized to buy $650M+ of product to vest shares, potentially creating "forced" revenue that may not reflect underlying market demand. The competitive dynamic is intensifying as Marvell enters with PCIe 7.0 solutions and Broadcom pushes Ethernet-based scale-out fabrics that bypass the need for discrete PCIe switching. Ultimately, Astera faces a "pincer movement" from customer self-design and tier-1 semiconductor giants aggressively defending their data center footprints.

Pitch Summary:
European Residential REIT is a self-liquidating Dutch residential property vehicle trading at a steep discount to realizable NAV as it winds down its portfolio. With roughly €350–380m of remaining assets and manageable leverage, the trust has already demonstrated its ability to sell properties at or above IFRS appraisals. The investment case is not growth-driven but catalyst-driven, with asset sales, debt repayment, and cash distributions steadily returning capital to investors. At current prices, units trade at a 35–45% discount to conservative NAV despite a clear and finite liquidation timeline. The remaining portfolio is modest in size, making execution risk manageable within a 12–18 month horizon. Upside is asymmetric, driven by cash realization rather than market sentiment or multiple expansion. Key risks include slower-than-expected asset sales, regulatory pressure on Dutch housing, and FX movements, but capital impairment risk appears limited given asset backing.

BSD Analysis:
ERE is a special-situation vehicle in "self-liquidation" mode, managing stabilized Dutch multi-family assets. Sector: The Dutch residential market is characterized by a structural supply-demand imbalance and a severe housing crisis, which sustains high valuations for privatized portfolios. Dynamics: The portfolio distribution is focused on secondary Dutch cities (the Randstad region), where institutional liquidity remains robust despite higher interest rates. The "dynamics" of this investment are purely driven by the disposal schedule; management has board approval to sell all remaining assets and terminate the REIT without further shareholder consultation. As of Q3 2025, the debt-to-gross book value remains low at ~31%, with no mortgage maturities until 2027, giving the trust a strong hand in negotiations. The main dynamic risk is the Dutch Tax Authority's ongoing reassessment of certain subsidiaries, which could impact the final net distribution amount. However, previous sales evidence suggests the asset-level premiums likely cushion these structural costs.

Pitch Summary:
…we are hopeful, just like in 2000–2002, when the tortoise ran out of gas, that a slice of the money which came out of the maniacal sectors will reach out-of-favor industries like energy (APA Corp. [APA], Diamondback Energy [FANG], ConocoPhillips [COP], Occidental Petroleum [OXY]), healthcare (Merck [MRK], Amgen [AMGN], UnitedHealth [UNH]) and homebuilders (D.R. Horton [DHI] and Lennar [LEN]), to name a few.

BSD Analysis:
Merck continues to ride Keytruda’s dominance, but the pipeline behind it is far deeper than investors credit. Oncology remains the core, but vaccines, cardiometabolic, and immunology add breadth. Cash flow is massive and redeployed into high-quality BD. Patent cliffs loom, but Merck has built one of the strongest R&D engines in large-cap pharma. Valuation remains reasonable for the reliability delivered. MRK is execution-first, drama-last. A defensive compounder with meaningful upside optionality.

Pitch Summary:
Our best-performing stocks in the quarter were D.R. Horton (DHI), APA Corp (APA), and Simon Property (SPG). APA continued to improve operating margins through workforce optimization and the sale of non-core assets. The Federal Reserve’s rate cuts and resilient consumer spending provided tailwinds for both D.R. Horton and Simon Property Group.

BSD Analysis:
Simon remains the heavyweight of global retail real estate, with Class-A malls that behave more like experiential town centers than traditional shopping centers. Occupancy is strong, rents are rising, and tenants need SPG’s foot traffic more than SPG needs tenants. The balance sheet is solid and development optionality remains valuable. Retail apocalypse narratives are stale; Simon’s assets are irreplaceable. Cash flow is resilient and dividend coverage safe. SPG is the luxury end of retail REITs — still undervalued relative to its asset quality. A fortress wrapped in a mall operator’s clothing.

Pitch Summary:
Our best-performing stocks in the quarter were D.R. Horton (DHI), APA Corp (APA), and Simon Property (SPG). … The Federal Reserve’s rate cuts and resilient consumer spending provided tailwinds for both D.R. Horton and Simon Property Group.

…we are hopeful, just like in 2000–2002, when the tortoise ran out of gas, that a slice of the money which came out of the maniacal sectors will reach out-of-favor industries like … homebuilders (D.R. Horton [DHI] and Lennar [LEN])…

BSD Analysis:
D.R. Horton is the undisputed execution king of U.S. homebuilders, with unmatched scale, land discipline, and cycle-resilient pricing power. Rate volatility matters less when you control the entry-level market the way DHI does. Margins remain impressive, and demand stays firm thanks to structural housing undersupply. Cash flow is enormous and reinvested with precision. Unlike peers, DHI doesn’t need a macro miracle — it just needs normalcy. The market still undervalues how bulletproof this operator is. A long-term compounding machine in U.S. housing.

Pitch Summary:
APA was one of the fund’s top contributors this quarter, improving operating margins through workforce optimization and the sale of non-core assets. Management has continued to emphasize capital discipline, strong balance sheet management, and accretive portfolio rationalization. Lower rig counts and sector consolidation point to tightening supply and a constructive outlook for energy equities.

BSD Analysis:
APA remains a high-beta oil name with strong cash generation and upside leverage to commodity prices. Suriname remains the wildcard — enormous potential, enormous uncertainty. Base operations produce solid free cash flow, and buybacks remain aggressive. The market punishes APA for past missteps, but current execution is cleaner. This is a company with real geopolitical optionality layered on top of a sturdy cash engine. If Suriname hits, APA rerates violently. A boom-or-steady commodity play with asymmetric upside.

Pitch Summary:
Unicredit (UCG IM) has been a model of this copycat game. Banks take in deposits and lend them out to collect the spread. This is referred to as net interest margins. This is a key income-generating part of most banks. Beyond this, you’d want to understand how efficiently they produce this income.

In discussions our firm has had with Andrea Orcel, CEO of Unicredit, he has explained how important his bank’s operating platform is and the investments they’ve made. We have seen how their partial ownership of Alpha Bank in Greece has improved the technology spending of that bank as they have been able to leverage Unicredit’s agreements to save cost in hosting and software.

This cost savings is where the industry is headed. Scaled players become part or whole owners of another bank. They are able to reduce the cost of operating the acquired bank and the combined businesses run a higher return on equity. This is the simple math that Orcel has been seeking to enact in European banks, including his investment in Commerzbank, while the Germans drag their feet.

BSD Analysis:
UniCredit is one of Europe’s most improved banks, with ruthless cost discipline, strong capital returns, and a CEO who actually understands shareholder value. Net interest income remains robust, and capital ratios are among the best in Europe. The market is still anchored to UniCredit’s messy past, not its clean balance sheet and modernized operations. Buybacks are massive and ongoing. Loan quality is better than investors assume, and geographic mix is more stable than headlines imply. This is one of the strongest European bank turnarounds in years. A financial powerhouse priced like a recovery story.

Pitch Summary:
Cenovus and Strathcona are currently bidding for ownership of MEG Energy (MEG), which we also own. The potential accretion from a transaction of this scale, combined with both bidders’ ability to achieve meaningful cost synergies from readily attainable efficiencies, has drawn increased investor interest to these names.

The oil business is seeing the same thing. Our ownership of MEG Energy (MEG CN) has been the talk of the town in Calgary and parts of New York’s merger arbitrage desks over the last 90 days. MEG was put in play by another company we own, Strathcona Resources (SCR CN) in May. Another holding of ours, Cenovus Energy (CVE CN), has made a rival offer…

SCR’s last offer for MEG sits close to $30, but the value of MEG is only going up as this auction works itself out. Our interest for fund shareholders is an all-stock offer that defers capital gains from the highest price bidder. At this point, that continues to look like it will be SCR.

BSD Analysis:
MEG is a pure torque play on Canadian heavy oil, with a low-decline asset base and aggressive balance-sheet improvement. Every dollar of FCF is going straight into buybacks, shrinking the float at a pace few energy names match. Differentials remain a wildcard, but MEG’s cost structure gives it strong resilience. The market still prices MEG like it’s levered and unstable — outdated thinking. The company is lean, focused, and increasingly shareholder-driven. If crude stays even mid-cycle, MEG’s equity math becomes compelling. High-beta energy with real discipline.

Pitch Summary:
The biggest contributors for the quarter were Cenovus Energy (CVE CN), Strathcona Resources (SCR CN), and Frontline (FRO NO). As many investors may know, Cenovus and Strathcona are currently bidding for ownership of MEG Energy (MEG), which we also own.

MEG was put in play by another company we own, Strathcona Resources (SCR CN) in May. Another holding of ours, Cenovus Energy (CVE CN), has made a rival offer that taught us all what we need to know about the financial attractiveness to scale a couple of oil companies in a merger.

Adam Waterous, Chairman of SCR, has been very aware of this value and has done an excellent job of communicating the value creation in the oil and gas business like Orcel has in banking. … Adam has talked about $42 per share in statements he has made publicly. Why would he talk of such large numbers? He is directly communicating how much value creation there is in a transaction for MEG. SCR’s last offer for MEG sits close to $30, but the value of MEG is only going up as this auction works itself out.

BSD Analysis:
Strathcona is a rising Canadian E&P force with scale, longevity, and a disciplined capital-return mindset. Heavy-oil and thermal assets create powerful operating leverage when prices rise. The company’s growth trajectory is far faster than market recognition — it behaves like a major but trades like a mid-cap. Balance sheet discipline is solid, cash flow strong, and decline rates low. Strathcona isn’t well-known yet, which is exactly the opportunity. As production grows and capital returns ramp, institutions will notice. A high-quality Canadian operator at an early stage of market discovery.

Pitch Summary:
The biggest contributors for the quarter were Cenovus Energy (CVE CN), Strathcona Resources (SCR CN), and Frontline (FRO NO). As many investors may know, Cenovus and Strathcona are currently bidding for ownership of MEG Energy (MEG), which we also own. The potential accretion from a transaction of this scale, combined with both bidders’ ability to achieve meaningful cost synergies from readily attainable efficiencies, has drawn increased investor interest to these names.

In their presentation to investors in August, Cenovus communicated that they expected $400 million in annual savings when you combine the two businesses. This is a massive number as MEG only does $3 billion in revenues. It would roughly double the returns on capital for MEG over the last 12 months.
For pre-tax cost savings like this, an investor may give this a multiple of about eight times the cost savings to understand the long-term value obtained. This would be $3.2 billion CAD as of MEG’s price on September 30, 2025. This represents about 45% of MEG’s market cap while they are in an open auction taking their price higher. This $3.2 billion CAD doesn’t include the $600 million CAD tax benefit that Cenovus would recognize in the next 12 months from existing net operating losses that MEG also has.

BSD Analysis:
Cenovus is printing cash from its oil sands + downstream integration model, which gives it margin resilience no matter what crude does. Debt is dropping fast, buybacks are aggressive, and the portfolio is built to survive any price cycle. Oil sands assets have long lives and low decline rates, giving Cenovus enviable durability. Yet the stock still trades at a deep discount to its FCF power. Operational hiccups have scared off tourists, but the underlying engine is strong. If the market prices CVE like a stable cash machine instead of a Canadian cyclical, rerating is material. Quietly one of the best value plays in large-cap energy.

Pitch Summary:
This quarter, we feature Stran & Company (SWAG) - a $33M market cap promotional products company based in Quincy, MA that we have closely followed since its 2021 IPO. Because the company is headquartered in our backyard, we have been able to meet with management a number of times and attended the company’s most recent open house, where we were able to speak with many of Stran’s customers. With no sell-side coverage and daily volume of ~$160K, Stran exemplifies the type of overlooked small-cap opportunity we seek out. Stran designs and sources custom branded merchandise, which is an effective and low-cost marketing channel for its clients. We were initially drawn to the company’s overcapitalized balance sheet, increasingly strong position in the highly fragmented promotional products industry, and emerging scale advantages as Stran’s revenues have grown from $30M in FY19 to over $100M today. For example, many companies in the promotional products industry use wholesalers to purchase promotional products - with growing scale and purchasing power, Stran now has direct relationships with manufacturing facilities in the U.S. and overseas, allowing it to be more competitive on pricing to win new customers. We anticipate this scale dynamic to improve as the company grows, providing further opportunities for organic revenue expansion. The company is also pursuing an acquisition strategy to expand into new industry verticals, thereby growing its customer base and increasing cross-sell opportunities. In our view, Stran’s expanding scale and customer base are strengthening its competitive advantage. This scale-begets-scale dynamic is one that we always look for in any micro-cap stock, particularly one that is profitable. … Stran reported its 2Q25 results after the close on August 12, where it reported total and organic revenue growth of 95.2% and 30.4%, respectively, while producing positive GAAP net income and FCF. … We believe the company could generate nearly $0.40 in free cash flow per share in FY29, implying an EV/FCF multiple of 3x at current net cash levels. A 15x multiple on FCF in 2029 would imply a target price of $6.00 per share. With the stock around $1.72 today and around $1.12 in net current assets per share, we believe Stran presents a fairly asymmetric risk/reward profile.

BSD Analysis:
Stran operates in the promotional-products and branded-merchandise space — low margin, but sticky when executed properly. Growth-by-acquisition gives it scale opportunities, but integration remains a risk. Revenue visibility is decent, though profitability is inconsistent. The company’s niche is defensible, but small-cap liquidity and volatility keep institutions away. STRN is priced for trouble, not for improvement. If margin discipline continues, valuation has room to move. A speculative but improving microcap.

Pitch Summary:
The second biggest detractor in our portfolio this quarter was Lucid Diagnostics. Lucid currently markets an FDA-approved DNA test for the early detection of esophageal precancer and cancer, known as EsoGuard. We believe EsoGuard has a legitimate multi-billion dollar plus market opportunity due to its unique capabilities, outstanding clinical data and attractiveness as a minimally invasive test for nonendoscopic precancer testing. The patient need for this test is large, the company’s clinical data is strong, and it has a unique position in the marketplace. The only thing holding back accelerating adoption has been a lack of reimbursement. Though we have been aware of Lucid and EsoGuard’s potential for some time, we wanted further validation on the part of clinicians before taking on the risk of owning this stock in front of an upcoming rather binary Medicare approval decision. Fortunately, we were able to listen to a publicly held conference call with a Medicare Contractor Advisory Committee that took place in early September. It included an extensive discussion by several independent experts and physicians that have expertise in esophageal cancer and have analyzed EsoGuard’s clinical data. The universal sentiment from this independent panel was very positive towards the test and its ability to save lives. We walked away from that call convinced that the product had strong clinical utility and had a good probability of receiving Medicare reimbursement in the next few quarters, which would then hopefully pave the way for broader commercial reimbursement and meaningful revenues for Lucid. Aside from some uncertainty around the clinical utility of EsoGuard prior to the CAC meeting of medical experts, the other reason we did not own the stock before this clinical validation was concern about the company doing multiple dilutive stock offerings in recent months, as well as the unusual corporate structure of the company and its relationship with “sister company” PavMed (PAVM). Despite these ongoing concerns, we chose to buy the stock following the CAC call, as we think EsoGuard could be worth well over $1B and the company’s fully-diluted market cap was under $250M. Even if some value leaks to PavMed and assuming we were diluted again to ensure ample liquidity for the company, there is substantial potential upside in the stock and we believe the potential value of this product is truly underappreciated by the market. The reason shares of Lucid are one of our main detractors this past quarter is that days after this very positive call, the company did yet another stock offering at a meaningful discount to market, though the stock has subsequently recovered some of those losses this quarter. As we have said before, in the world of micro-cap, it is not unusual to encounter difficult decisions around companies that have been diluters and where there are concerns around corporate governance. In general, we try to avoid these situations. However, in this case, we were willing to compromise, as there is potentially huge value in EsoGuard and this has been independently verified by a large sample of independent experts. Furthermore, most serial diluters with sub-optimal corporate structures have no real product, they are simply stock promoters. In this highly unusual case, we do believe there is real value in Lucid Diagnostics, even with some future leakage. Furthermore, though we find the relationship with PavMed unusual, to their credit, the company has been very open and transparent with all disclosures around that relationship and its implications for the common stock shareholders of both companies. The realization of value from this investment will hopefully come if/when Lucid receives Medicare reimbursement for EsoGuard. Much like Torrid, when reviewing this loss from a process not outcome perspective, we would have made this investment again, but the position size should have been smaller to account for the risk of future dilution on such positive news, as well as the binary risk around Medicare reimbursement.

BSD Analysis:
Lucid’s early-detection esophageal cancer platform has strong clinical logic, but commercialization has been slow and capital-intensive. Reimbursement momentum is improving, which could unlock adoption in a meaningful way. The technology is differentiated, yet the market doubts the company’s ability to scale. Cash burn is high and patience is limited — understandable for a small-cap diagnostics story. But if uptake begins to accelerate, LUCD’s TAM is substantial. This is a binary med-tech catalyst story. High risk, real upside.